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Abstract This study investigates relationships between
EMT and bone invasion by OSCC. Three OSCC cell lines,
SCC25, HN5, and Tca8113 were artificially induced to
display EMT by adding 5 ng/mL of TGF-b1 to culture
media for 1–3 days. Cell morphology and phenotypic
changes was examined by immunocytochemical staining of
CK and VIM. EMT markers, cell-invasion factors, and
osteoclast-related molecules were analysed at mRNA,
gelatine and protein levels by real-time PCR, gelatine
zymography and Western blotting respectively. Mature
osteoclasts differentiated from Raw264.7 cells were treated
by conditioned medium (CM) of OSCC cells with/without
TGF-b1. Immunohistochemistry was performed to validate
proteins of CK, VIM, E-cad and Snail1 in OSCC tissue
samples with bone invasion. Results showed minimal
staining of VIM was found in SCC25 and HN5, while
Tca8113 cells stained strongly. EMT markers Twist1 and
N-cad were up-regulated; Snail1 and E-cad down-regulated
in all cells. Of factors associated with invasion, MMP-2 was
unchanged and MMP-9 increased in SCC25 and Tca8113,
while MMP-2 was increased and MMP-9 unchanged in
HN5. For osteoclast-related molecules, both MT1-MMP
and RANKL were up-regulated, while OPG was down-
regulated in all cells. CM of OSCC cells pre-treated with
TGF-b1 showed to prolong survival of osteoclasts up to
4 days. All target molecules were validated in OSCC sam-
ples of bone invasion. These findings suggest that TGF-b1
not only induces EMT to increase the capacity of OSCC for
invasion, but also promotes factors which prolong osteoclast
survival. TGF-b1 may enhance the ability of MMP2/9 in
resorbing bone and favouring invasion of cancer cells.
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Abbreviation
OSCC Oral squamous cell carcinoma
EMT Epithelial-mesenchymal transition
CM Conditioned medium
TGF-b1 Transforming growth factor-b1
MMP-2 Matrix metalloproteinase-2
MMP-9 Matrix metalloproteinase-9
CK Cytokeratin
VIM Vimentin
E-cad E-cadherin
N-cad N-cadherin
MT1-MMP Membrane type 1 matrix metalloproteinase
TIMP-1 Tissue inhibitor of matrix metalloproteinase-1
TIMP-2 Tissue inhibitors of matrix metalloproteinase-2
RANKL Receptor activator of nuclear factor (NF)-jB
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Introduction
Bone invasion is one of the most frequent complications of
OSCC, especially those arising in the retromolar trigone,
buccal sulci, gingiva, floor of mouth and hard palate. The
incidence is as high as 56 % of investigated patients [1, 2].
Bone involvement contributes to increased morbidity, higher
recurrence and mortality rates [3, 4]. Despite improvements in
current treatment modalities—surgery, radiotherapy and
adjunctive chemotherapy, cure rates for these patients remain
low. Fortunately, there have been considerable advances in
understanding the molecular mechanisms of the process of
neoplasia, so that the possibility of individualised biotherapies
is increasingly recognised. Understanding and interfering
with molecules involved in bone invasion may enhance such
therapeutic options [5].
When epithelial neoplasms metastasise to bone, a
vicious circle is established between the malignant cells
themselves, and bone tissue. This also occurs when carci-
noma invades bone directly, such as with oral cancer [6].
On the one hand, tumour cells secrete multiple factors to
alter the bone environment and induce the formation of
osteoclasts; while on the other hand, osteoclasts release
growth factors from the bone matrix, which then stimulate
tumour growth and further accelerate bone destruction
[7, 8]. Of these, TGF-b1, which has been widely studied, is
a major bone-derived factor responsible for driving this
vicious circle. TGF-b1, along with activins, inhibins, and
bone morphogenetic proteins (BMP), are members of the
TGF-b super family [9, 10]. For cancer cells, TGF-b1 can
become an oncogenic factor to induce proliferation, inva-
sion and immunosuppression during tumour progression
[11, 12] and is implicated in bone metastasis from several
solid tumours. Mohammad et al. showed that the inhibitor
of TGF-b receptor I (TbRI) kinase, effectively reduced
osteolytic lesions and tumour burden in mice with malig-
nant melanoma [13]. Ganapathy et al. demonstrated that
two types of TGF-b pathway antagonists (1D11 and
LY2109761) significantly decreased metastasis to lung and
bone of nude mice, injected with cells of human basal-like
breast cancer [14]. As for bone invasion by OSCC, a recent
study found that TbRI was expressed by 18 of 21 patients
with gingival SC, and the inhibitor of TbRI greatly reduced
the bone destruction caused by OSCC cells in vitro [15].
Additionally, Prime et al. [16] observed that the OSCC cell
lines, which were resistant to inhibitory effects of TGF-b1,
formed significantly more primary tumours, with high
incidence of mandibular invasion, when injected through
the floor of the mouth of athymic mice.
In the present study, we found that conditioned medium
(CM) of osteoblasts induced gene expression level changes
of OSCC cells [17], for example, Twist1, was up-regulated
in these cells after such treatment. The expression of
MMP-2 protein level was increased, while MMP-9 was
decreased. Furthermore, immunohistochemical staining of
Twist1, MMP-2 and MMP-9 was observed in clinical
samples of OSCC patients with bone invasion. We specu-
late that these changes in gene expression may be caused
by growth factors in the CM. Since TGF-b1 was present in
significant amounts in the bone microenvironment, and
proven to induce EMT in various epithelial cells in vitro
[12], we attempted to determine the effects of TGF-b1 on
OSCC cells and the way they interact with osteoclasts.
Materials and methods
Reagents and antibodies
Recombinant TGF-b1 was purchased from R&D Systems
(Minneapolis, USA). DMEM, foetal bovine serum (FBS),
trypsin–EDTA, anti-CK (anti-pan cytokeratin), anti-VIM
and anti-E-cad were purchased from Invitrogen. Anti-
Twist1, anti-Snail1, anti-MT1-MMP, anti-tissue inhibitors
of MMP (TIMP1), anti-TIMP2 and anti-OPG were bought
from Santa Cruz Biotechnology; while anti-RANKL and
anti-a-Tubulin were from Abcam. Anti-N-cad was pur-
chased from Cell Signalling. Primary antibodies were
either mouse or rabbit against human. Secondary antibod-
ies, goat anti-mouse IgG and goat anti-rabbit IgG, were
from Bio-Rad Laboratories.
Indirect co-cultures
OSCC cell lines of SCC25, HN5 and Tca8113 were kindly
supplied by Associate Professor Nick Saunders (The Uni-
versity of Queensland, Australia), Professor Ming Wei
(Griffith University, Australia) and Professor Qian Tao (Sun
Yat-sen University, China) respectively. These cells were
routinely maintained in DMEM containing 10 % FBS.
Human foetal osteoblasts (hFOB) were obtained from
American Type Tissue Collection (ATCC, Rockville, USA),
and grown in DMEM/F12 with 10 % FBS plus 300 lg/mL
geneticin (G418) at 34 C in an incubator. CM [17] was
collected from OSCC cell lines SCC15 and SCC25, and from
hFOB, and used for indirect co-culture: OSCC cells were
treated with CM of hFOB cells for 48hs. To block the
endogenous TGF-b1 secreted by hFOB cells, TGF-b
inhibitor (SB431542, 188 nM, Sigma) was used in CM of
hFOB to treat OSCC cells for 48 h. To examine the effects of
TGF-b1 on OSCC cells, equal numbers of SCC25, HN5 and
Tca8113 cells were plated in serum-free medium, starved for
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12 h, and then treated with TGF-b1 (5 ng/mL) for 0,
1–3 days. Culture medium was changed daily.
Immunocytochemistry
After the treatment with TGF-b1 for 0–3 days, OSCC cells
were fixed with 70 % ethanol for 10 min and permeabili-
zed by 0.1 % Triton X-100 for 5 min. Non-specific binding
of the antibodies was avoided by blocking with 5 % BSA
in PBS for 30 min, followed by incubation with primary
antibodies of CK (1:50) and VIM (1:50) overnight at 4 C,
and then with secondary antibodies for 1 h at 37 C. Non-
immune serum instead of the primary antibody was used as
negative controls. Three washes with PBS were applied
between each step of antibody incubation. Sites of binding
were visualized using liquid diaminobenzidine (DAB)
? substrate ? chromogen system (DAKO), counterstained
with Mayer’s haematoxylin, and photographed by a Nikon
OXM1200 digital camera with the Act-1 program. Immu-
nostaining intensity was scored according to percentage of
tumour cells with positively-stained: designated as ? where
\20 % of cells were stained; ?? where \40 % were
stained; ??? where [60 % were stained.
Real-time PCR
Total RNA was isolated from OSCC cells before and after
TGF-b1 treatment using the PureLink RNA Mini Kit
(Invitrogen, USA), and reverse transcribed to cDNA using
the iScript cDNA Synthesis Kit (Bio-Rad) based on the
manufacturer’s instructions. Quantitative gene analysis was
performed for Twist1, Snail1, E-cad, N-cad, MMP-2,
MMP-9, TIMP-1, TIMP-2, MT1-MMP, RANKL and OPG
by using EXPRESS SYBR GreenER qPCR Supermix
Universal Kit (Invitrogen, USA) and the icycler iQ5 Real-
time PCR system (Bio-Rad, USA). The data were nor-
malized to the internal control, GAPDH to obtain DCt.
Finally fold-change of genes of interest relative to
untreated samples was reported by 2-DDCt method. Primers
used in this study are listed in Table 1.
Gelatine zymography
Equal numbers of OSCC cells of SCC25, HN5, and
Tca8113 were planted in 6-well plates with the density of
106 cells per well. CM from OSCC cells before and after
TGF-b1 treatment was used for Gelatine Zymography. CM
of HT 1,080 cells served as the positive control. 20 lL of
each sample was mixed with non-reducing sample buffer
(62.5 mM Tris–HCl, pH 6.8; 4 % SDS; 25 % glycerol;
0.01 % Bromophenol Blue) and electrophoresed on 10 %
precast denaturing SDS polyacrylamide gels with gelatine
(Bio-Rad Lab, CA, USA). Gels were washed in the
commercial renature solution (2.5 % Triton X-100) for
40 min at room temperature and incubated in development
solution (50 mM Tris; 200 mM NaCl; 5 mM CaCl2;
0.02 % Brij-35) at 37 C for 40 h. Finally, gels were
stained with Coomassie Brilliant Blue R-250 (Sigma,
USA) for 1 h at room temperature and progressively
destained until clear bands appeared against the blue
background.
Western blotting
Total protein was extracted from OSCC cells before and
after TGF-b1 treatment using lysis buffer (Thermo scien-
tific, USA). The protein concentration was determined
using a BCA Protein Assay Kit (PIERCE, USA). 40 lg of
protein was subjected to SDS–PAGE with 10 % poly-
acrylamide gels. Proteins were transferred to PVDF
membranes, and blocked with 5 % non-fat dry milk in Tris-
buffered saline (TBS) for 1 h at room temperature. The
membranes were then incubated with primary antibodies of
Twist1 (1:200), Snail1 (1:200), E-cad (1:200), N-cad (1:100),
TIMP-1 and TIMP-2 (1:200), MT1-MMP (1:200), RANKL
(1:500), OPG (1:200) and a-Tubulin (1:3,000) overnight at
4 C, washed twice and incubated with horseradish per-
oxidase-conjugated (HRP) secondary antibodies for 1 h at
room temperature. The protein bands were detected by
SuperSignal WestPico Chemiluminescent Substrate (Thermo
scientific) and visualised using the VersaDoc-MP Imaging
Systems (Bio-Rad).
Osteoclasts differentiation from RAW264.7 cells
Mature osteoclasts were generated from the murine macro-
phage cell line of RAW264.7, which was kindly given by
Dr Stephen Hamlet (Griffith University). RAW264.7 cells
were cultured in DMEM with 10 % FBS at 37 C in a
humidified 5 % CO2 atmosphere. To obtain osteoclasts, these
cells were seeded in a 96-well plate at a density of 1.25 9 104
cells/well, and supplemented with 50 ng/mL of recombinant
mouse RANKL (R&D Syetems, USA) on day 1 and day 3.
Mature osteoclasts were observed on day 5. Afterwards, the
entire culture medium was changed into CM of OSCC
cells pre-treated with or without TGF-b1 (5 ng/mL). After
4 days’ treatment, TRAP staining (STrACP, Nanjing
Jiancheng, China) was performed and photographed using a
Nikon OXM1200 digital camera with the Act-1 program.
Validation of EMT related markers in clinical samples
To validate proteins of CK, VIM, E-cad and Snail1, the
archival blocks from 12 patients whose OSCC showed
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invasion of bone were randomly examined. The Human
Research Ethical Clearance was granted by both Griffith
University and Queensland Health prior to the com-
mencement of the study. Serial tissue sections (5 lm
thickness) were dewaxed, rehydrated and treated with
0.3 % hydrogen peroxide in PBS. Antigen retrieval was
performed in 0.2 % citrate buffer (pH 6.0) by heating
sections in a microwave oven (2 9 4 min). After non-
specific binding was blocked with 5 % BSA in PBS for
30 min, sections were incubated with primary antibodies of
CK (1:50), VIM (1:50), E-cad (1:80) and Snail1 (1:100)
overnight at 4 C. Sections were then treated with the anti-
mouse/rabbit secondary antibodies (Envision ? Systems)
for 30 min, followed by DAB detection solution (Dako,
Botany, Australia) for a few minutes at room temperature.
Primary antibodies were replaced by non-immune serum as
negative controls. Sections were counterstained with
Mayer’s haematoxylin, dehydrated, and mounted with
DPX (BDH Laboratory, Poole, England). The final results
were visualized by a light microscopy and photographed
using an Olympus Bx60 digital camera with the CellSens
software.
Statistical analysis
Data analysis was performed using SAS program (SAS
version 8.1, USA). A paired Student t test was used to
compare two means. A p value of less than 0.05 was
regarded as significant.
Results
Indirect co-cultures between osteoblasts and OSCC
cells
Results showed that Twist1 expression was up-regulated in
OSCC cells after the treatment with CM from cells of
hFOB. MMP-2 was increased while MMP-9 was dec-
reased in all OSCC cells. To verify the effect of TGF-b
secreted by hFOB in the co-cultures, hFOB was pretreated
with the inhibitor of TGF-b (SB431542) followed by the
co-culture. It was found the reduction of expressions of
Twist-1 and MMP-2, but slightly increased MMP-9, which
suggested bioefficiency of the inhibitor (Fig. 1a). Immu-
nochemical staining of these molecules was observed in 12
clinical samples of OSCCC patients with bone invasion
(Fig. 1b): H&E staining showed an infiltrative pattern of
bone invasion with tumour cells invading into the bone,
and osteoclasts accumulated in resorption lacunae. Faint
staining of Twist1 was noted in the cytoplasm of OSCC
cells, but strongly in osteoclasts. MMP-2 was weakly
expressed in OSCC cells and osteoclasts, while MMP-9
was clearly localized within the cytoplasm of OSCC cells
and especially in the nuclei of osteoclasts.
The cell morphology of OSCC remained no change,
neither was in the staining intensity of cytokeratin changed
(Fig. 2a). A summary of the staining results is shown in
Table 1 Primer Sequences Used in Real-time PCR
Genes Primers Length
(bp)
Twist1 Forward: 50-TGTCCGCGTCCCACTAGC-30
Reverse: 50-
TGTCCATTTTCTCCTTCTCTGGA-30
63
Snail1 Forward: 50-
TGCAGGACTCTAATCCAAGTTTACC-30
Reverse: 50-GTGGGATGGCTGCCAGC-30
71
E-cad Forward: 50-
GAACAGCACGTACACAGCCCT-30
Reverse: 50-
GCAGAAGTGTCCCTGTTCCAG-30
76
N-cad Forward: 50- GACGGTTCGCCATCCAGAC-30
Reverse: 50-TCGATTGGTTTGACCACGG-30
66
MMP-2 Forward: 50-
GACATACATCTTTGCTGGAGAC-30
Reverse: 50-TTCAGGTAATAGGCACCCTT-
30
180
MMP-9 Forward: 50-CTTCACTTTCCTGGGTAAG
G-30
Reverse: 50-CACTTCTTGTCGCTGTCAAA-30
105
TIMP-1 Forward: 50-
GGAGAGTGTCTGCGGATACTTC-30
Reverse: 50-
GCAGGTAGTGATGTGCAAGAGTC-30
100
TIMP-2 Forward: 50-
ACCCTCTGTGACTTCATCGTGC-30
Reverse: 50-
GGAGATGTAGCACGGGATCATG-30
129
MT1-
MMP
Forward: 50-
CCTTGGACTGTCAGGAATGAGG-30
Reverse: 50-
TTCTCCGTGTCCATCCACTGGT-30
146
RANKL Forward: 50-
CAGAAGATGGCACTCACTGCA-30
Reverse: 50-CACCATCGCTTTCTCTGCTCT-
30
203
OPG Forward: 50-
GGAACCCCAGAGCGAAATACA-30
Reverse: 50-
CCTGAAGAATGCCTCCTCACA-30
225
GAPDH Forward: 50-TGCACCACCAACTGCTTAGC-
30
Reverse: 50-
GGCATGGACTGTGGTCATGAG-30
87
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Fig. 2b. However, weak staining of VIM was found in
SCC25 and HN5 following the treatments with TGF-b1.
Same staining of VIM was also found in Tca8113 cells
before and after the treatments (Fig. 2b).
mRNA level changes of selected genes after treatment
with TGF-b1
Real-time PCR was utilized to examine mRNA levels of
selected genes. The EMT markers, Twist1 and N-cad, were
shown to have increased expression, while Snail1 and
E-cad were down-regulated in all cells after treatment with
TGF-b1 (Fig. 3a–c). The cell invasion factor MMP-2 was
not affected in SCC25 and Tca8113 cells, while it was
induced in HN5 cells. Conversely, MMP-9 was un-affected
in HN5, but was up-regulated in SCC25 and Tca8113 cells.
Furthermore, TIMP-1 was decreased in SCC25 and
Tca8113 cells, while the expression of HN5 was increased.
TIMP-2 was induced in SCC25 and Tca8113, but sup-
pressed in HN5 cells. For osteoclast-related molecules, the
expression of both MT1-MMP and RANKL was increased,
but OPG was suppressed in all cells.
Changes of zymogenic activity of MMP-2 and MMP-9
after treatments with TGF-b1
Zymography was used to detect the zymogenic activities of
MMP-2/-9 (Fig. 4a). Results showed that TGF-b1 increased
the activities of MMP-9 in SCC25 and Tca8113 cells, and
the activities of MMP-2 in HN5 cells (Fig. 4b).
Expression of protein changes of targeted genes
after treatment with TGF-b1
Western blotting was performed to validate expressions of
TGF-b1 targeted genes at the protein level. Comparing
with results of real-time PCR, the expression pattern was
almost the same with a few differences (Fig. 5a–c). For
EMT markers, Twist1 was increased while Snail1 was
decreased in all OSCC cells. E-cad was slightly suppressed
in SCC25 cells while it was dramatically suppressed in
HN5 cells, but not detected in Tca8113 cells. N-cad was
found to be induced in all cells tested. TIMP-1 was down-
regulated and TIMP-2 was un-changed in both SCC25 and
Tca8113 cells; while TIMP-1 was un-affected and TIMP-2
was suppressed in HN5 cells. For osteoclast-related
Fig. 1 Results of the indirect co-culture between hFOB and OSCC
cells. a Western blotting shows that Twist1 expression is up-regulated
after the treatment with CM from hFOB cells. The expression of
MMP-2 is increased, while MMP-9 decreases in all OSCC cells.
Expression of Twist-1, MMP-2 by OSCC cells was reduced, while
MMP-9 was increased after the blockage of TGF-b1 by using
SB431542. b H&E staining shows an infiltrative pattern of bone
invasion with osteoclasts accumulating in resorption lacunae (a).
Weak immunohistochemical staining of Twist1 shows in the
cytoplasm of OSCC cells, but strongly stained in osteoclasts (b).
MMP-2 is weakly expressed in OSCC cells and osteoclasts (c), while
MMP-9 is clearly localized within the cytoplasm of OSCC cells,
especially in the nuclei of osteoclasts (d)
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molecules, MT1-MMP was up-regulated in all cells. Fur-
thermore, RANKL was induced in SCC25 and Tca8113
cells, while it was not detected in HN5 cells. Expressions
of OPG were decreased in all OSCC cells.
CM of OSCC cells treated with TGF-b1 prolonged
the survival of mature osteoclasts
Mature osteoclasts generated from the murine macrophage
cell line, RAW264.7, were treated with CM of OSCC cells
with or without TGF-b1. Since our earlier results had
shown significant changes of EMT markers on days 1 and
2, CM of OSCC cells were here treated with TGF-b1 for 24
or 48 h. Similar results were observed on each day as
follows: comparing with CM from OSCC cells without
TGF-b1, CM from OSCC cells pre-treated with TGF-b1
prolonged the survival of osteoclasts up to 4 days (Fig. 6a–b).
Osteoclasts with continual RANKL treatment became
apoptotic on day 4, TGF-b1 (5 ng/mL) also induced the
apoptosis of mature osteoclasts on day 4 (Fig. 6a–b).
Validation of targeted molecules in human OSCC
tissues with bone invasion
The H&E staining on archived OSCC tissue sections
obtained from 12 patients with bone invasion showed an
infiltrative pattern, and cancer cells invaded into the bone
tissue (Fig. 7a). Using immunohistochemistry, it was found
that CK was strongly expressed in the cytoplasm of OSCC
cells, while VIM was weakly stained within the cytoplasm
of OSCC cells (Fig. 7b–c). For E-cad, weak cytoplasmic
expression was found in OSCC cells (Fig. 7d). Stronger
cytoplasmic expression of Snail1 was observed in cyto-
plasm of OSCC cells (Fig. 7e). Control sections were
negatively stained (Fig. 7f).
Discussion
TGF-b is well known to be a key initiator of EMT, which
can induce artificial EMT of normal epithelial cells as well
as of malignant cells [12, 18]. In our present study, we
Fig. 2 Immunohistochemical staining of CK and VIM in OSCC
cells. a Similar staining patterns are visualised at each time point: CK
staining has no change in the epithelial OSCC cells (arrows,
bar = 25 lm); weak staining of VIM is shown in SCC25 and HN5,
while VIM is strongly stained in Tca8113 cells before and after the
treatment (arrows, bar = 25 lm). Results represent three indepen-
dent experiments. b Summary of the immunohistochemical staining
results
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Fig. 3 Real-time PCR in three
OSCC cell lines (a SCC25,
b HN5, c Tca8113) before and
after treatments with TGF-b1.
The expression of EMT
markers, Twist1 and N-cad, are
shown to have increased
expression, while Snail1 and
E-cad are down-regulated in all
types of cells following the
treatments with TGF-b1. The
cell invasion factor, MMP-2, is
not affected in SCC25 and
Tca8113 cells, but the
expression of MMP-2 is induced
in HN5 cells. Conversely,
MMP-9 is not affected in HN5
cells, while it is up-regulated in
SCC25 and Tca8113 cells.
Moreover, TIMP-1 is
suppressed in SCC25 and
Tca8113 cells, while the
expression of HN5 cells is
increased. On the other hand,
TIMP-2 is induced in SCC25
and Tca8113 cells, but is
suppressed in HN5 cells. For
osteoclast-related molecules,
both MT1-MMP and RANKL
are induced while OPG is
suppressed in all cells tested.
Data are shown as mean ± SD
of three independent
experiments
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Fig. 4 Gelatin Zymography in
OSCC cells before and after
treatment with TGF-b1. a TGF-
b1 mediates the activities of
MMP-9 in both SCC25 and
Tca8113 cells, while the activity
of MMP-2 is also increased in
HN5 cells. b The intensity of
bands shown in the zymograph
is converted to the figure using
semi-quantitative
histodensitometry analysis. The
results are averaged in three
independent experiments
Fig. 5 Western blotting analysis of three OSCC cell lines (a SCC25,
b HN5, c Tca8113) before and after treatment with TGF-b1. For EMT
markers, Twist1 expression is increased while Snail1 is decreased in
all these cells. E-cad is slightly suppressed in SCC25 while it is
dramatically suppressed in HN5, and not detected in Tca8113 cells.
However, expression of N-Cad demonstrates to be switched on in all
types of OSCC cells. TIMP-1 is down-regulated, but TIMP-2 has no
change in both SCC25 and Tca8113 cells. While TIMP-1 is not
affected, TIMP-2 is suppressed in HN5 cells. For osteoclast-related
molecules, MT1-MMP is up-regulated in all OSCC cells. RANKL is
induced in SCC25 and Tca8113 cells, while it is not detected in HN5
cells. Expressions of OPG are decreased in all OSCC cells. These
results are representative of three independent experiments
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observed that cell morphology in these OSCC cells cultures
was not changed, most cells remaining polygonal during
3 days’ treatment with TGF-b1. This is consistent with our
earlier studies in which morphological evidence of EMT
took several days longer to become manifest [19]. For these
EMT markers, typical ‘‘cadherin switching’’, a term
referring to the ability of E-cad expression and activity to
switch on the expression of N-cad [20], was shown in all
cell lines tested. Twist1 expression was increased while
Snail1 was decreased in all cells after being treated with
TGF-b1. Both Twist1 and Snail1 are nuclear transcription
regulators of EMT which interact with each other, not
always in a consistent fashion [21–23]. For example,
Twist1 was found to act upstream from Snail and induce
EMT-like transformation in a mouse xenograft model with
human breast cancer [21]; while a comparison of benign
Fig. 6 TRAP staining of the mature osteoclasts generated from
Raw264.7 cells. a The positive control group of osteoclasts (with
continual RANKL treatment) become apoptotic on day 4 (TRAP,
bar = 25 lm). TGF-b1 (5 ng/mL) also directly induces the apoptosis
of mature osteoclasts on day 4 (TRAP, bar = 25 lm). Comparing
with CM of OSCC cells without TGF-b1, CM of OSCC cells pre-
treated with TGF-b1 may prolong the survival of mature osteoclasts
up to 4 days (arrows, TRAP, bar = 25 lm). b Numbers of osteo-
clasts are counted with 4 fields randomly selected. Data are shown as
M ± SD of three independent experiments (*, p \ 0.05)
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and malignant pheochromocytoma suggested that Snail
target on Twist promoting malignant transformation [22].
Whilst the reasons for these different interpretations arising
in different experimental situations are currently unknown,
the present study, consistent with previous co-cultures, and
the increased expression of Twist1 suggesting TGF-b1 be
the active factor in CM which initiates EMT.
The gelatinases MMP-2/-9 are associated with EMT to
increase tumour invasion and metastasis [24]. We previ-
ously reported that expression of MMP-2/-9 in OSCC cells
was, in relation to EMT, triggered by TGF-b1 [19]. MMP-
2 and MMP-9 are secreted but rapidly become inhibited by
the specific endogenous inhibitors of TIMP-1 and TIMP-2
[25]. In the present study, TIMP-1 expression decreased
and TIMP-2 increased in both SCC25 and Tca8113 cells.
Conversely, MMP-2 expression was up-regulated and
MMP-9 was not changed, while TIMP-1 expression was
up-regulated and TIMP-2 was down-regulated in HN5
cells. The increased expression of MMP-9 or MMP-2 in
these OSCC cells suggested similar responses to TGF-b as
shown before [26, 27]. This may establish an autocrine
loop: both MMP-2 and MMP-9 can mediate the cleavage
of latent TGF-b complexes [28]. Moreover, an autocrine
regulation of MMP and TIMP was confirmed that endog-
enous MMP-9 was inhibited by TIMP-1, and TIMP-2 was
the primary inhibitor of MMP-2. It is currently unknown
whether this regulation is direct or indirect action of TGF-
b. Indeed, many signalling pathways have been involved in
the regulation of TGF-b, MMP and TIMP family members,
which will be explored in future studies.
Osteoclast-related factors not only include molecules
which induce the formation of osteoclasts, but also those
proteolytic enzymes which help to degrade the non-miner-
alized osteoid [29]. The gelatinases MMP-2 and MMP-9
Fig. 7 Validation of targeted molecules in OSCC tissue with bone
invasion using the immunohistochemical analysis. a The H&E
staining shows the infiltrative pattern of bone invasion by OSCC
into the bone tissue. b Immunohistochemistry shows that CK is
strongly expressed in the cytoplasm of OSCC cells at the centre of
tumour, while weak staining is found in cancer cells at the front of
bone resorption sites. c The VIM is weakly stained within the centre
of tumour, but strongly stained in OSCC cells at the front of bone
resorption sites. d Cytoplasmic expression of E-cad is weakly at the
centre of tumour, but no staining in OSCC cells is shown at bone
resorption sites. e The expression of Snail-1 is strongly present
throughout the cytoplasm of all OSCC cells. f The negative control
shows no staining in OSCC cells
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participate in the recruitment of osteoclast precursors and
the differentiation of osteoclasts during the development
and growth of normal tissues [30]. In addition to the gela-
tinase activities of MMP-2/-9, MT1-MMP functions as a
sheddase, releasing non-ECM substrates such as RANKL
[31]. A recent report demonstrated that MT1-MMP derived
from prostate cancer cells enhanced their migration through
an autocrine pathway of MT1-MMP/RANK/RANKL [32].
The present study has shown that MT1-MMP was increased
in OSCC cells after being treated with TGF-b1. To establish
whether MT1-MMP has similar autocrine effects in OSCC
cells as demonstrated for prostate cancer cells, we analysed
the expression of RANKL and OPG and found the
expression of RANKL was increased, but OPG was
decreased in OSCC cells. Therefore, the suppression of
OPG expression tipped the ratio of RANKL to OPG in
favour of RANKL, which may lead to enhance osteo-
clastogenesis resulting in bone resorption [33].
We next wished to investigate the effects of molecules
released by OSCC cells on osteoclast behaviour (Pathway
C, Fig. 8). Unexpectedly, when CM of OSCC cells was
added into cultures of Raw264.7 cells, we could not see
osteoclast formation (data not shown). Thereafter, we
firstly obtained mature osteoclasts from Raw 264.7 cells,
and treated them with CM of OSCC cells grown with or
without TGF-b1. Our results showed that CM from cells
pre-treated with TGF-b1 prolonged osteoclast survival up
to 4 days compared with CM without TGF-b1. With con-
tinued RANKL treatment, mature osteoclasts became
apoptotic on day 4. TGF-b1 (5 ng/mL) also induced
apoptosis of these osteoclasts. Thus, our results indicated
that factors in OSCC cells treated by TGF-b1 might block
its apoptotic effects, and promote survival of osteoclasts.
Cytokines induced by TGF-b1 may include pathways of
apoptosis, such as caspase or BCL family members, which
needs to be further investigated.
The question of whether changes in the fibroblast-
shaped neoplastic cells are necessary for these to acquire
osteomimetic characteristics remains [34, 35]. Davies et al.
[36] found that transfection of TGF-b1 into a rat kerati-
nocyte cell line caused changes in cell morphology from
polygonal to spindle: these cells subsequently formed
tumours in nude mice, and increased local bone resorption.
Takayama et al. [37] reported that TGF-b1 caused EMT of
SCCVII cells, and they found EMT-like changes through
resected human mandibles with gingival SCC, in which
immunohistochemical staining of E-cad was weak in
tumour mass-margin comparing with the tumour mass-
centre. Although changes of cell morphology (indicative of
EMT) was not observed during the 3 day treatments with
TGF-b1, OSCC cells coordinated the survival of osteo-
clasts. Further validation of molecules in OSCC tissue
samples found stronger staining of CK and Snail1, while
weaker staining of VIM and E-cad, which are consistent
with Takayama’s results. Although these findings are
indirect observation, which are not substantial, they sug-
gest that partial EMT may exist in the bone invasive pro-
gression of OSCC. Whether morphologic and phenotypic
changes of malignant keratinocytes are necessary for bone
invasion is the focus of future work [38].
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